Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy

Hepato-Gastroenterology

Volumn 52, Issue 66, 2005, Pages 1654-1658

  Saisho, Toshimitsu ^a   Okusaka, Takuji ^a   Ueno, Hideki ^a   Morizane, Chigusa ^a   Okada, Shuichi ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Biliary tract cancer; Chemotherapy; Prognosis; Prognostic factors

Indexed keywords

ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; CISPLATIN; EPIRUBICIN; FLUOROURACIL; GIMERACIL; LACTATE DEHYDROGENASE; METHOTREXATE; MITOMYCIN C; OTERACIL POTASSIUM; TEGAFUR; UFT; UNCLASSIFIED DRUG;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BILIARY TRACT CANCER; CANCER CHEMOTHERAPY; ENZYME BLOOD LEVEL; FEMALE; HAZARD ASSESSMENT; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGE FACTORS; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; BIOPSY, NEEDLE; CAUSE OF DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PALLIATIVE CARE; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEX FACTORS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 28544437472     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. North JH Jr., Pack MS, Hong C, Rivera DE: Prognostic factors for adenocarcinoma of the gallbladder: an analysis of 162 cases. Am Surg 1998; 64:437-440.
2. Donohue JH, Stewart AK, Menck HR: The national cancer database report on carcinoma of the gallbladder. Cancer 1998; 83:2618-2628.
3. Nakamura S, Suzuki S, Konno H, Baba S, Baba S: Outcome of extensive surgery for TNM stage IV carcinoma of the gallbladder. Hepatogastroenterology 1999; 46:2138-2143.
4. Doglietto GB, Alfieri S, Pacelli S, Mutignani M, Costamagna G, Carriero C, Giorgio AD, Papa V: Extrahepatic bile duct carcinoma: a western experience with 118 consecutive patients. Hepatogastroenterology 2000; 47:349-354.
5. Blom D, Schwartz SI: Surgical treatment and outcomes in carcinoma of the extrahepatic bile ducts: the University of Rochester experience. Arch Surg 2001; 136:209-215.
6. Okada S, Ishii H, Nose H, Yoshimori M, Okusaka T, Aoki K, Iwasaki M, Furuse J, Yoshino M: A phase II study of cisplatin in patients with biliary tract carcinoma. Oncology 1994; 51:515-517.
7. Jones DV Jr, Lozano R, Hoque A, Markawitz A Patt YZ: Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. J Clin Oncol 1996; 14:2306-2310.
8. Patt YZ, Jones DV Jr, Hoque A, Lozano R, Markawitz A, Raijman I, Lynch P, Charnsangavej C: Phase II trial of intravenous fluorouracil and subcutaneous Interferon alfa-2b for biliary tract cancer. J Clin Oncol 1996; 14:2311-2315.
9. Ducreux M, Rougier P, Fandi A, Clavero-Fabri MC, Villing AL, Fassone F, Fandi L, Zarba J, Armand JP: Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol 1998; 9:653-656.
10. Raderer M, Hejna MHL, Valencak JB, Kornek GV, Weinländer GS, Bareck E, Lenauer J, Brodowicz T, Lang F, Scheithauer W: Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology 1999; 56:177-180.
11. Todoroki T, Takahashi H, Koike N, Kawamoto T, Kondo T, Yoshida S, Kashiwagi H, Otsuka M, Fukao K, Saida Y: Outcomes of aggressive treatment of stage IV gallbladder cancer and predictors of survival. Hepatogastroenterology 1999; 46:2114-2121.
12. Backes BG, Hauptmann S, Booking A: Carcinoma of the extrahepatic biliary system: correlation of clinical, pathological, histological and DNA-cytometric parameters with prognosis. Anticancer Res 2000; 20:1163-1168.
13. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649-655.
14. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 63:457-481.
15. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35:1-339.
16. Cox DR: Regression models and life tables [with discussion]. J R Stat Soc Ser B 1972; 34:187-220.
17. Serott MN, Bajorin DF, Wong GYC, Tao Y, Chapman PB, Templeton MA, Houghton AN: Prognostic factors in patients with malignant melanoma. Cancer 1993; 72:3091-3098.
18. Falconer JS, Fearon KC, Ross JA, Elton R, Wigmore SJ, Garden OJ, Carter DC: Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 1995; 75:2077-2082.
19. Gripp S, Hilgers K, Wurum R, Schmitt G: Tymoma: prognostic factors and treatment outcomes. Cancer 1998; 83:1495-1503.
20. Lagerwaard FJ, Levendag PC, Nowak PJCM, Eijkenboom WMH, Hanssens PEJ, Schmitz PIM: Identification of prognostic factors in patients with brain metastases: A review of 1292 patients. Int J Radiat Oncol Biol Phys 1999; 43:795-803.
21. Paesmans M, Sculier JP, Lecomte J, Thriaux J, Libert P, Sergysels R, Bureau G, Dabouis G, Van Cutsem O, Mommen P, Ninane V, Klastersky J, for the European Lung Cancer Working Party: Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up op 5 years. Cancer 2000; 89:523-533.
22. Tartour E, Blay JY, Dorval T, Escudier B, Mosseri V, Douillard JY, Deneux L, Gorin I, Negrier S, Mathiot C, Pouillart P, Fridman WH: Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: a French multi-institutional study. J Clin Oncol 1996; 14:1697-1703.
23. Ueno H, Okada S, Okusaka T, Ikeda M: Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 2000; 59:296-301.
24. Tas F, Aykan F, Alici S, Kaytan E, Aydiner A, Topuz E: Prognostic factors in pancreatic carcinoma. Serum LDH levels predict survival in metastatic disease. Am J Clin Oncol 2001; 24:547-550.
25. Wolf M, Holle R, Hans K, Drings P, Havemann K: Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): The role of sex as a predictor for survival. Br J Cancer 1991; 63:986-992.
26. Wolters U, Stützer H, Isenberg J: Gender related survival in colorectal cancer. Anticancer Res 1996; 16:1281-1290.
27. Tas F, Aykan NF, Aydiner A, Uygun K, Basaran M, Camlica H, Topuz E: The roles of chemotherapy and surgery in gastric carcinoma and the influence of prognostic factors on survival. Am J Clin Oncol 2000; 23:53-57.
28. Miller JG, Neil SM: Gender and cutaneous melanoma. Br J Dermatol 1997; 136:657-665.